Table 3.
Mortality | T2DM Relative Risk (95% CI) |
---|---|
Breast cancer | 1.24 (0.95–1.62) |
Colorectal cancer | 1.20 (1.03–1.40) |
Endometrial cancer | 1.23 (0.78–1.93) |
Hepatocellular carcinoma | 2.43 (1.67–3.55) |
Total cancer mortality | 1.16 (1.04–1.30) |
Incidence | |
Breast cancer | 1.20 (1.12–1.28) |
Colorectal cancer | 1.27 (1.21–1.34) |
Endometrial cancer | 1.97 (1.71–2.27) |
Hepatocellular carcinoma | 2.31 (1.87–2.84) |
Intrahepatic cholangiocarcinoma | 1.97 (1.57–2.46) |
Pancreatic cancer | 1.95 (1.66–2.28) |
Total cancer incidence | 1.10 (1.04–1.17) |
Relative risk compared to non-diabetic individuals. Summary random effects estimate from 27 meta-analyses derived from Tsilidis et al. [77].